Category: drug_metabolism
Distinct from estrogen biosynthesis (see steroid_hormone_biosynthesis + aromatase_androgen_receptor_axis): this pathway covers the *clearance* arm — how circulating estradiol is hydroxylated, conjugated, and excreted. Step 1: CYP1A1 / CYP1A2 / CYP1B1 hydroxylate estradiol at C2 (2-OH-E2, weakly estrogenic, anti-proliferative metabolite) or C4 (4-OH-E2, genotoxic/quinone-forming metabolite — the carcinogenicity branch). Step 2: COMT methylates 2-OH-E2 → 2-MeO-E2 (anti-angiogenic, inactivated). Step 3: UGT (UGT1A1, UGT2B7) glucuronidates hydroxylated estrogens → biliary + renal excretion. Step 4: SULT (SULT1E1) sulfates estrogens for inactivation. Step 5: Enterohepatic recycling — gut β-glucuronidase deconjugates biliary estrogen-glucuronides → reabsorption (raised by constipation + dysbiosis). Phytochemical modulators: sulforaphane (broccoli) is a canonical Nrf2 activator → induces phase-2 enzymes (UGT, GST, COMT) → shifts 2-OH/4-OH ratio favorably; EGCG (green tea catechins) competitively inhibits COMT but induces phase-2 conjugation; resveratrol modulates ERα/β + induces phase-2 enzymes; curcumin upregulates phase-2 conjugation via Nrf2; genistein (soy isoflavone) is a partial ER agonist competing for ERα binding, also induces phase-2 enzymes; milk-thistle/silymarin upregulates hepatic phase-2 and antioxidant defenses. Clinical importance: chronic estrogen excess + skewed 2-OH/4-OH ratios are mechanistically linked to estrogen-driven cancers (breast, endometrial). Phytochemical induction of the 2-OH + glucuronidation arms is the molecular basis of cruciferous-vegetable + green-tea anti-cancer epidemiology. Cross-links: [[conjugation_phase2_overview]], [[nrf2_keap1_antioxidant_response]], [[steroid_hormone_biosynthesis]], [[estrogen_receptor_genomic_nongenomic]].